MX2009009996A - Composicion y metodo para tratar diabetes y trastornos metabolicos. - Google Patents

Composicion y metodo para tratar diabetes y trastornos metabolicos.

Info

Publication number
MX2009009996A
MX2009009996A MX2009009996A MX2009009996A MX2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A MX 2009009996 A MX2009009996 A MX 2009009996A
Authority
MX
Mexico
Prior art keywords
composition
metabolic disorders
treat diabetes
diabetes
subject
Prior art date
Application number
MX2009009996A
Other languages
English (en)
Spanish (es)
Inventor
Milton Joseph Ahrens
Daryl Lee Thompson
Original Assignee
Atm Metabolics Lllp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atm Metabolics Lllp filed Critical Atm Metabolics Lllp
Publication of MX2009009996A publication Critical patent/MX2009009996A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009009996A 2007-03-19 2008-03-11 Composicion y metodo para tratar diabetes y trastornos metabolicos. MX2009009996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89548607P 2007-03-19 2007-03-19
PCT/US2008/056474 WO2008115723A1 (en) 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Publications (1)

Publication Number Publication Date
MX2009009996A true MX2009009996A (es) 2010-01-20

Family

ID=39590291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009996A MX2009009996A (es) 2007-03-19 2008-03-11 Composicion y metodo para tratar diabetes y trastornos metabolicos.

Country Status (8)

Country Link
US (2) US7943164B2 (enExample)
EP (1) EP2129371B1 (enExample)
JP (1) JP2010522185A (enExample)
CN (1) CN101674821B (enExample)
BR (1) BRPI0809047B8 (enExample)
CA (1) CA2685031A1 (enExample)
MX (1) MX2009009996A (enExample)
WO (1) WO2008115723A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522185A (ja) * 2007-03-19 2010-07-01 エーティーエム メタボリックス エルエルエルピー 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物
JP5524466B2 (ja) * 2008-10-31 2014-06-18 ユニテックフーズ株式会社 中性風味デザートベース
US9918489B2 (en) * 2008-12-17 2018-03-20 Mark Gorris Food-based supplement delivery system
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
JP2011001311A (ja) * 2009-06-19 2011-01-06 Pola Chemical Industries Inc 熱産生タンパク質発現促進剤
RU2496331C1 (ru) * 2009-08-10 2013-10-27 Стукли-Ван Кэмп, Инк. Способ суспендирования флавоноида в напитке
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI527581B (zh) 2010-01-29 2016-04-01 亞培公司 包含ｈｍｂ的無菌包裝營養液
CA2785528C (en) 2010-01-29 2015-07-14 Abbott Laboratories Nutritional emulsions comprising calcium hmb
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US8372447B2 (en) * 2010-08-03 2013-02-12 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
CA2835753C (en) * 2011-06-06 2020-03-10 Unilever Plc An edible composition comprising a flavonoid aglycone and a flavonoid monoglucoside
JP2014521060A (ja) 2011-06-28 2014-08-25 コーニンクレッカ フィリップス エヌ ヴェ 体液の検査用手段
CN102772424B (zh) * 2012-06-13 2014-01-08 浙江大学 新橙皮苷在制备防治糖尿病药物中的应用
KR101396059B1 (ko) * 2012-06-25 2014-05-16 중앙대학교 산학협력단 소귀나무잎으로부터 분리된 신규 황산염 페놀성 화합물 및 이의 항산화 및 항염 용도
EP2867663B1 (en) 2012-06-29 2022-12-07 Koninklijke Philips N.V. Processing of bound and unbound magnetic particles
WO2014001985A1 (en) 2012-06-29 2014-01-03 Koninklijke Philips N.V. Processing of fluids containing interfering particles
CN104471374B (zh) 2012-07-18 2019-05-21 皇家飞利浦有限公司 对具有目标成分的样本流体进行处理
WO2014083474A1 (en) 2012-11-30 2014-06-05 Koninklijke Philips N.V. Capture particle for selectively binding a target molecule
AU2015248506B2 (en) 2014-04-13 2020-09-03 Marmar Investment Sp. Z O.O. Dietary compositions for reducing blood glucose levels and for weight management
EP3161485B1 (en) 2014-06-25 2018-10-31 Koninklijke Philips N.V. Biosensor for the detection of target components in a sample
WO2016088029A1 (en) * 2014-12-01 2016-06-09 Cape Kingdom Nutraceuticals (Pty) Ltd Therapeutic compositions
EP3274714B1 (en) 2015-03-26 2019-07-03 Koninklijke Philips N.V. Manufacturing of a biosensor cartridge
CN105816473B (zh) * 2015-07-06 2018-04-10 武汉华纳联合药业有限公司 一种黄酮苷类组合物及其制剂和制法
JP2017105745A (ja) * 2015-12-02 2017-06-15 共栄化学工業株式会社 皮膚外用剤
US20180133243A1 (en) * 2016-11-16 2018-05-17 Holista Colltech Ltd Method and composition for crude formulations of fortified sugar for glycemic control
TWI667036B (zh) 2017-04-03 2019-08-01 大江生醫股份有限公司 植物萃取物於調控ｐｄｇｆｃ、ｆｇｆ２、ｉｇｆ１ｒ、ｐｔｇｉｓ、ｎｏｓ３、ｅｄｎ１、ｐｌａｔ、ｐｒｏｃ、ｖｗｆ、ｆ３、ｓｅｒｐｉｎｅ１、ｉｌ－８、ｉｃａｍ１、ｖｃａｍ１及ｃａｓｐ８基因的用途
US20220257561A1 (en) * 2019-06-07 2022-08-18 Advanced Delivery Labs Llc Compositions and methods for improving wellness
CN111387504A (zh) * 2020-04-15 2020-07-10 武汉森澜生物科技有限公司 一种含绿原酸和柚皮苷的活性提取物、提取方法及其用途
CN119255715A (zh) * 2022-03-28 2025-01-03 路易斯安娜州立大学监测委员会，农业和机械学院 用于提高胰岛素敏感性的协同作用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134233B2 (ja) 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
EP0969743B1 (en) * 1997-03-20 2004-09-15 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
US7229651B2 (en) 1997-08-06 2007-06-12 Melaleuca, Inc. Dietary supplements containing natural ingredients
KR20000019716A (ko) 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
US20020068704A1 (en) 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
CA2405348A1 (en) 2000-04-13 2001-11-01 Ocean Spray Cranberries, Inc. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US20030108627A1 (en) * 2001-09-25 2003-06-12 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
AU2003261903A1 (en) * 2002-11-06 2004-06-07 Kao Corporation Blood fluidity improving agent
US7270837B2 (en) 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
US20060188590A1 (en) 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
US20070092454A1 (en) 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
JP2010522185A (ja) * 2007-03-19 2010-07-01 エーティーエム メタボリックス エルエルエルピー 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物

Also Published As

Publication number Publication date
BRPI0809047B1 (pt) 2020-09-01
JP2010522185A (ja) 2010-07-01
WO2008115723A1 (en) 2008-09-25
US20110118345A1 (en) 2011-05-19
EP2129371B1 (en) 2021-05-05
CA2685031A1 (en) 2008-09-25
US8198319B2 (en) 2012-06-12
BRPI0809047B8 (pt) 2021-05-25
EP2129371A1 (en) 2009-12-09
CN101674821B (zh) 2013-06-26
BRPI0809047A2 (pt) 2014-09-02
US7943164B2 (en) 2011-05-17
US20080234364A1 (en) 2008-09-25
CN101674821A (zh) 2010-03-17

Similar Documents

Publication Publication Date Title
MX2009009996A (es) Composicion y metodo para tratar diabetes y trastornos metabolicos.
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
ECSP10010015A (es) Inhibidores de proteasoma
MX386489B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
BR112013009142A2 (pt) "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
GB0920703D0 (en) Compositions containing satiogens and methods of use
BRPI0920670A8 (pt) composição nutritiva para promover o desenvolvimento e crescimento sadios
BR112012023021A2 (pt) compostos de indazol e seus usos
BR112013024025A8 (pt) Composição fluida destinada a ser aplicada na pele
UY34950A (es) Composición y método adecuado para enfermedades provocadas por fitopatógenos y método para proteger sustancias naturales de origen animal y/o vegetal
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
BRPI0924653B8 (pt) composto de ferro-oligossacarídeo, composição e uso de deste composto
BRPI0818007A2 (pt) composição para regular o metabolismo lipídico
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
BR112012018843A2 (pt) radioimunoconjugado que se liga a cd37humano composição farmacêutica uso do radioimunoconjugado metodo para tratamento de uma malignidade de célula b e kit para a produçãoradioimunoconjugado
EP2063881A4 (en) COMPOSITION AND METHOD FOR THE EFFECTIVE AND SAFE ADMINISTRATION OF HALOPYRUVATE FOR THE TREATMENT OF CANCER
BRPI1014362A2 (pt) método e composição para sincronizar o tempo de inseminação
BRPI0905995A2 (pt) "composição conservante para ser adicionada a um produto formulado, produto a ser conservado, método de fabricação do produto e uso de uma composição"
BRPI0910575A2 (pt) métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição
CL2009001139A1 (es) Composicion que comprende un lisofosfolipido para tratar los efectos de la inflamacion.

Legal Events

Date Code Title Description
FG Grant or registration